Longeveron presents 5-year survival data for HLHS cell-based therapy at CHSS Annual Meeting in 2024.

Longeveron Inc. will present five-year survival data from its ELPIS I study on cell-based therapy for Hypoplastic Left Heart Syndrome (HLHS) at the CHSS Annual Meeting on October 27-28, 2024, in Chicago. HLHS is a rare congenital heart defect affecting about 1,000 U.S. infants annually, often requiring complex surgeries. The company's investigational product, Lomecel-B™, aims to improve transplant-free survival rates.

October 09, 2024
3 Articles